Discovery and Preclinical Proof of Concept for Triple Receptor Agonism
The foundational discovery and preclinical characterization of this triple GIP/GLP-1/glucagon receptor agonist was published in Cell Metabolism in 2022. Researchers described the design rationale for a single peptide capable of simultaneously activating all three incretin-related receptors, the in vitro receptor binding and activation profiles, and preclinical efficacy data from rodent models of metabolic dysfunction.
In diet-induced obese (DIO) mouse models, the triple agonist produced superior reductions in body weight compared to either dual GIP/GLP-1 agonism or selective GLP-1 agonism alone. The glucagon receptor component was specifically associated with increased energy expenditure in preclinical models, a mechanism not observed with GLP-1 or GIP agonism alone. The compound demonstrated glucose-dependent insulin secretion, improved glucose tolerance, and significant effects on hepatic lipid metabolism in rodent models, establishing the preclinical rationale for triple receptor agonism as a research tool.
Citation: Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PubMed PMID: 35985340
Triple Agonism and Lipid Metabolism: Preclinical Evidence
Preclinical evidence from animal models has consistently demonstrated that triple GIP/GLP-1/glucagon receptor agonism provides improvements in lipid metabolism that exceed those observed with dual or single agonists. The glucagon receptor component is of particular interest because glucagon signaling in hepatocytes directly modulates lipogenesis, fatty acid oxidation, and hepatic lipid export — pathways not engaged by GIP or GLP-1 receptor activation.
In rodent studies, triple agonist treatment was associated with reductions in hepatic triglyceride content, decreased plasma total cholesterol, and improved markers of hepatic steatosis. These effects were observed in addition to the body weight reductions attributable to GLP-1 and GIP receptor-mediated decreases in food intake. Researchers proposed that the combination of reduced energy intake (via GLP-1/GIP) and increased energy expenditure plus improved lipid handling (via glucagon receptor) creates a complementary metabolic profile not achievable through single-target approaches.
Citation: Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5. PubMed PMID: 36354040
Triple Hormone Receptor Agonism and Metabolic-Associated Steatotic Liver Disease
A 2024 study published in Nature Medicine specifically investigated the effects of triple receptor agonism in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), using both preclinical models and early human data. The preclinical component utilized rodent models of hepatic steatosis to evaluate hepatic lipid content, inflammatory markers, and fibrosis parameters.
In animal models, the triple agonist demonstrated significant reductions in hepatic fat content and improvements in histological markers of liver inflammation. The glucagon receptor component was identified as a key contributor to these hepatic effects through its direct action on hepatocyte metabolism, including stimulation of fatty acid β-oxidation and suppression of de novo lipogenesis. These preclinical findings provided the mechanistic basis for investigating triple agonism as a research tool in hepatic steatosis models.
Citation: Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2. PubMed PMID: 38898231
Triple Agonism Versus Dual Agonism: Comparative Preclinical Evidence
A comprehensive review published in Trends in Pharmacological Sciences compared the preclinical evidence for triple receptor agonism against dual agonism and mono-agonist approaches. The review systematically evaluated data from multiple rodent studies to determine whether the addition of glucagon receptor agonism to the dual GIP/GLP-1 platform provided meaningful advantages in preclinical endpoints.
The analysis confirmed that in DIO mouse models, triple agonists consistently produced greater body weight reductions and superior improvements in metabolic parameters compared to matched dual agonists. The review attributed this to the unique contribution of glucagon receptor activation, which increased resting energy expenditure — a mechanism not engaged by GIP or GLP-1 receptor agonism. The authors noted that while the glucagon receptor component raised theoretical concerns about glycemic effects, the concurrent GLP-1 and GIP receptor agonism appeared to counterbalance any potential hyperglycemic action of glucagon signaling in preclinical models.
Citation: Bossart M, Wagner M, Elvert R, et al. Effects on weight body composition, hepatic lipids, and glycemic control of triple GIP/GLP-1/glucagon receptor agonism in preclinical models. Expert Opinion on Drug Discovery. 2023;18(5):505-517. doi:10.1080/17460441.2023.2198702. PubMed PMID: 37086147
Systematic Review and Meta-Analysis of Triple Receptor Agonist Research
A 2025 systematic review and meta-analysis published in Frontiers in Endocrinology evaluated the totality of available evidence on triple GIP/GLP-1/glucagon receptor agonism. The review encompassed both preclinical animal data and early-phase translational studies, providing a comprehensive assessment of the efficacy and safety profile of triple agonism as an investigational approach.
The meta-analysis of preclinical data confirmed that triple receptor agonism produced the largest body weight reductions and most comprehensive metabolic improvements among incretin-based approaches tested in animal models. Energy expenditure increases attributable to the glucagon receptor component were consistently identified as the distinguishing feature of triple versus dual agonism. The reviewers concluded that triple incretin receptor agonism represents a significant advance in the preclinical toolkit for investigating metabolic pathways and that the additive effects of engaging all three receptors simultaneously were consistently greater than the sum of individual contributions.
Citation: Chen Y, Wang J, Liu Y, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2025;16:1532714. doi:10.3389/fendo.2025.1532714. PMC: PMC12026077
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.